NEWS & PERSPECTIVES
Psychedelics News
Curated updates on microdosing, research, policy, and community.
The latest
Protected: MAPS and Founder Rick Doblin Submit Written Comments to FDA on Psychedelic-Assisted Therapy Standards
There is no excerpt because this is a protected post.
Podcast: Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing
A Nevada licensing issue is delaying US production of Wafermine, a ketamine wafer being developed by iX Biopharma under a nearly $41 million Defense Department contract for battlefield pain.
The Defense Department awarded Singapore-based iX Biopharma a nearly $41 million non-competitive contract in February to develop Wafermine. Its US manufacturing partner, Nevada-based Orion Specialty Labs, is FDA-regis...
Lobe Sciences appointed Tracy L. Goeken, M.D., as chief medical officer to lead studies for its L-130 and S-100 programmes.
Dr Goeken joined Lobe Sciences on 20 October 2026, bringing more than 20 years of clinical development, regulatory strategy and medical affairs experience. He will oversee work on L-130, a psilocin-based candidate for...
MAPS and founder Rick Doblin submitted written comments to the FDA on standards for psychedelic-assisted therapy.
MAPS and its founder, Rick Doblin, submitted written comments to the US Food and Drug Administration on standards for psychedelic-assisted therapy. No further details about the comments or proposed standards are avail...
Does the menstrual cycle change the psychedelic experience? 5 Questions with psychopharmacologists Natasha Mason and Eline Haijen-Bongers
Mason and Haijen-Bongers discuss how hormones might interact with psychedelic therapy.
Girona Listened to the Jungle: A Chronicle of the World Ayahuasca Forum
From the opening song of more than a hundred Indigenous spiritual leaders to the question of who decides what deserves the name of medicine: a chronicle of the three days in which Girona hosted the first World Ayahuas...
music for psych therapy
Plus, VR and psychedelics, save the toads, and psychedelics in Jamaica [...] Read More...
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies,…
The National Center for Natural Products Research at the University of Mississippi has applied to register as a bulk manufacturer of controlled substances.
The National Center for Natural Products Research at the University of Mississippi, also known as NCNPR, submitted an application to become a registered bulk manufacturer of basic classes of controlled substances. The...
Groff Health Inc. applied to the Drug Enforcement Administration to register as an importer of basic classes of controlled substances, with comments due by 18 November 2026.
Groff Health Inc. submitted an application to the Drug Enforcement Administration for registration as an importer of basic classes of controlled substances. The notice was dated 19 October 2026, and the comment period...
Groff NA Hemplex LLC applied to the US Drug Enforcement Administration to register as an importer of basic classes of controlled substances.
Groff NA Hemplex LLC submitted an application to import basic classes of controlled substances. The Drug Enforcement Administration published the notice on 19 October 2026, with comments accepted until 18 November 2026.
Scottsdale Research Institute has applied to register as a bulk manufacturer of basic classes of controlled substances.
Scottsdale Research Institute submitted an application to the Drug Enforcement Administration to be registered as a bulk manufacturer of basic classes of controlled substances. The notice opened a public comment perio...
Organic Standards Solutions International, LLC has applied to register as an importer of basic classes of controlled substances.
The Drug Enforcement Administration published the application on 19 October 2026. Public comments are open until 18 November 2026, with further information on the drugs covered in supplementary material.
NRx Pharmaceuticals completed three GMP validation lots and two years of room-temperature stability testing for preservative-free ketamine ahead of the 10 November 2026 FDA deadline.
NRx said the three commercial-process lots met GMP requirements, while stability data showed no deterioration in purity, potency or sterility after two years without preservatives. Commercially releasable supply is on...